InterMune Reports Third Quarter 2008 Financial Results and Business ...(compared with $12.5 millionin the same p...)

R&D expenses were $78.3 million in the first nine months of 2008, a 3% decrease compared to $80.8 million in the same period of 2007. G&A expenses of $22.5 million in the first nine months of 2008 were approximately 2% lower than $23.0 million in the first nine months of 2007.

Third Quarter and Recent Highlights

Pirfenidone:

-- On October 16, Shionogi & Co., Ltd of Japan, which has rights to

pirfenidone in Japan, reported approval of its j-NDA to market

pirfenidone as Pirespa(R) in idiopathic pulmonary fibrosis (IPF).

-- InterMune confirmed excellent study conduct in its Phase 3 CAPACITY

program for pirfenidone in IPF, with 97% of surviving, transplant-free

patients having completed their Week 72 Study Visit.

-- InterMune today announced that all patients have now completed their

final study visit scheduled for 30 days after treatment completion.

Based on this timing, the company continues to expect to report top-

line results from its Phase 3 CAPACITY program in January or in

February of 2009.

ITMN-191 (R7227):

-- Announced in early September that InterMune had earned a $15 million

development milestone under its development collaboration with Roche

for ITMN-191. Under the terms of their 2006 collaboration agreement,

the responsibility for the clinical program for ITMN-191 is now in the

process of being transitioned to Roche which, starting in Phase 2, will

have primary responsibility for completing the global development and

registration program.

-- At the meeting of the American Association for the Study of Liver

'/>"/>